about
THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves' orbitopathyLoss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargementThe IGSF1 deficiency syndrome: characteristics of male and female patientsA novel albumin gene mutation (R222I) in familial dysalbuminemic hyperthyroxinemiaMutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans.Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.TBG deficiency: description of two novel mutations associated with complete TBG deficiency and review of the literature.Pituitary tumours: TSH-secreting adenomas.Medical Treatment of Graves' Orbitopathy.B Cell Activating Factor (BAFF) and BAFF Receptor Expression in Autoimmune and Nonautoimmune Thyroid Diseases.Fetal cell microchimerism: a protective role in autoimmune thyroid diseases.Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy.Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy.Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.A quantitative method for assessing the degree of axial proptosis in relation to orbital tissue involvement in Graves' orbitopathy.Increased loss of the Y chromosome in peripheral blood cells in male patients with autoimmune thyroiditis.The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.Therapeutic Outcomes of High-Dose Intravenous Steroids in the Treatment of Dysthyroid Optic NeuropathyTreatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open studyRituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathyNew immunomodulators in the treatment of Graves' ophthalmopathyEfficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppressionImpact of resistance to thyroid hormone on the cardiovascular system in adultsGraves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxisRituximab in the treatment of thyroid eye disease: science fiction?Treatment of pretibial myxedema with dexamethazone injected subcutaneously by mesotherapy needlesThyrotropin-secreting pituitary adenomas: outcome of pituitary surgery and irradiation
P50
Q26749195-81DE1931-6D7E-4723-B9E0-27F67C9057C2Q28279078-FE82096C-4481-46F9-BA73-6C31A216B066Q28300032-F2D33747-5AA8-4810-8BB4-ABACC1B6B3FFQ34313659-6FF8A8C3-4D0E-48D0-8726-DE42D7B72C9BQ34360195-79259405-5A7D-48A4-A04C-E61ACE3D1998Q35055076-33255858-F940-4D4D-83A3-471DBF7EDD48Q36583478-BF3CBDCE-2329-41C1-998E-40986C240D8CQ37640635-A2265822-6914-4FBB-97DF-28BA5804DD30Q38585021-B2EDD793-2C66-4E18-A142-7A72FA127EBFQ38848883-B80FD016-7B22-4054-B692-2ADD35DD4085Q41009244-31A28443-3724-48A4-AE1F-12A5833F3449Q42156382-442A65E1-27B5-48C4-AB39-4B5F005A0F53Q42503142-392E44FA-FBB7-44EE-9E17-762D6FF05209Q43042591-175DD53E-AA5C-47D2-9195-E63981B67F6EQ44463190-0528CDC4-10D5-4A23-96F1-F9943ABD27E3Q51373148-01568127-D1E3-499D-947D-9838BD44B3B7Q54756129-B833620A-EA08-4F5F-8435-099D7CC18BD7Q58763451-1DAE2D69-5623-421B-95C8-D05D98642A85Q79546631-9D65DE89-6E5F-4508-B6E3-FD42AF0B0BC9Q80689390-C74B836E-8115-471B-9473-91AAA4935E5DQ81097416-B93EEF33-7E4D-42D3-9CEB-19B26960768DQ82927501-91ECCDAE-02A5-469A-9833-E43823552EF8Q83814950-4F595CB8-B6A6-464A-A5E8-0A48E433AE5CQ84148014-A4AD3C01-673F-416C-B11B-23ACB7A00B97Q84746794-9C0B80AF-15BD-4668-BD9A-8B285890AC07Q86091517-AE8FABF2-A2BB-4F0D-8A09-2B164D94FC20Q87324192-D1E3BA79-A213-4FE3-A422-8B62B76D30BD
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-0340-9923
@en
name
Irene Campi
@ast
Irene Campi
@en
Irene Campi
@es
Irene Campi
@nl
type
label
Irene Campi
@ast
Irene Campi
@en
Irene Campi
@es
Irene Campi
@nl
altLabel
IRENE CAMPI
@en
prefLabel
Irene Campi
@ast
Irene Campi
@en
Irene Campi
@es
Irene Campi
@nl
P106
P1153
13007961800
P21
P31
P496
0000-0002-0340-9923